tbuckley/cabot-search huggingface dataset:
ENGOT-Ov41/GEICO-69-O/ANITA trial: A phase III randomized, double-blinded trial of platinum-based chemotherapy (CT) with or without atezolizumab (ATZ) followed by niraparib maintenance with or without ATZ in patients with recurrent ovarian, tubal or peritoneal cancer (OC) and platinum treatment-free interval (TFIp) &gt;6 months.
Authors: Antonio González-Martín, Nicoletta Colombo, Florian Heitz, Rene dePont Christensen, Frédéric Selle, Ignace Vergote, Ana Oaknin
Journal: Journal of Clinical Oncology (2019)

TPS5599 Background: Platinum-based CT is the treatment of choice for OC patients (pts) with TFIp &gt; 6 months suitable for platinum. Niraparib is an oral PARP inhibitor that significantly prolongs the progression-free survival (PFS) of OC pts when given as maintenance therapy after a response to platinum-rechallenge (both in gBRCA and non-gBRCA mutated pts). Atz is a humanized monoclonal antibody targeting PD-L1 that showed activity in heavily pretreated OC pts. Combination of anti-PD-L1 and CT may improve the activity of the anti-PD-L1 antibody by increasing the amount of antigens released after immunogenic cell death induced by CT. Combination of PARPi and anti-PD-L1/PD-1 has shown synergy in preclinical models and promising clinical activity in certain indications. Methods: ANITA (NCT03598270) is a phase III, randomized (1:1), double-blinded, multi-center study to assess the efficacy of the addition of Atz to platinum-based doublet CT followed by maintenance niraparib in patients with recurrent high grade serous or endometrioid OC with a TFIp &gt; 6 months. Approximately 414 patients with ECOG 0-1, known BRCA status, at least one measurable lesion and ≤ 2 prior lines will be randomized to placebo of Atz (Arm A) or Atz (Arm B) in combination with one of three possible standard platinum-based CT regimens (investigator’s choice) followed by maintenance niraparib in combination with placebo or Atz, according to randomization, if experiencing response or stable disease by RECIST after CT. Stratification factors: 1) Platinum-based regimen (paclitaxel-carboplatin vs gemcitabine-carboplatin vs PLD-carboplatin); 2) Platinum-free interval (6-12 vs &gt; 12 months); and 3) BRCA status (mutated vs non-mutated). Dose of Atz is 1200 mg q3 weeks or 840 mg q2 weeks depending on the platinum-based regimen selected. Niraparib initial dose (300 vs 200 mg) is decided based on body weight and platelet counts after CT according to RADAR analysis. Primary endpoint is PFS based on investigator assessment by RECIST v1.1. Clinical trial information: NCT03598270.
Diazepam Phlebitis
Authors: David F. Wehlage
Journal: JAMA (1973)

<h3>To the Editor.—</h3> The dearth of information available on the phlebitis caused by intravenously administered diazepam is well highlighted by the paper of Langdon et al inThe Journal(223:184, 1973). I would like to confirm their findings that phlebitis is a universal and absolute sequela of repeated intravenous injections of diazepam. I have used intravenously given diazepam in an area not described in the literature, namely as a premedicating and amnesic agent for electroconvulsive treatments. Psychiatrists have not taken full advantage of intravenously given diazepam as other specialists have in performing their diagnostic and treatment procedures. In replacing the traditional methohexital with intravenously given diazepam, the psychiatrist avoids much of the morbidity (respiratory depression, postictal agitation associated with methohexital, and electric convulsive therapy (ECT). I have found, however, that the daily use of an antecubital vein leads to a palpable venous induration with tenderness within three or four days.
Abstract 112: Patient derived models reveal impact of the tumor microenvironment on therapeutic response
Authors: Ayesha A. Shafi, Matthew J. Schiewer, Renée de Leeuw, Emanuela Dylgjeri, Peter A. McCue, Neelima Shah, Leonard Gomella, Costas Lallas, Edouard Trabulsi, Margaret Centerera, Theresa Hickey, Lisa Butler, Ganesh Raj, Wayne Tilley, Edna Cukierman, Karen E. Knudsen
Journal: Cancer Research (2019)

Abstract Prostate cancer (PCa) is the most common non-cutanenous cancer and the second leading cause of cancer-related death in American men. Androgen receptor (AR) is a hormone-activated transcription factor that plays an important role in both the development and progression of PCa. Androgen deprivation therapy is a common first-line therapy for disseminated disease. However, virtually all tumors become resistant to such therapy and the tumor recurs. Thus, there is a vital need for the development of novel, more effective drugs. One major hurdle in this aspect is the lack of adequate preclinical models. Current models do not effectively recapitulate the heterogeneity and the microenvironment of human PCa tumors, significantly hindering the ability to accurately predict therapeutic response. Our collaborative group has utilized and characterized a method to culture patient tumors ex vivo, termed Patient Derived Explant (PDE). This approach maintains the integrity of the native tumor microenvironment, tumor tissue morphology, and molecular signaling. Importantly, our PDE model can be manipulated both chemically (drugs/compounds) and genetically (shRNA) in order to determine specific reactions and mechanisms of response on individual tumor growth. Furthermore, with this model we can quantitatively assess drug efficacy on numerous parameters (i.e. AR levels, Ki67 staining, apoptosis screening, and desmoplasmic indices). Data to be discussed will assess the variances in response to AR-directed therapeutics and underlying mechanisms of action, while also utilizing TME characteristics as a means to predict response to therapy. In addition, we can potentially identify clinically relevant subpopulations of patients and molecularly profile their cultured tissue to uncover new pathways for therapeutic intervention. Thus, the PDE model allows for a comprehensive evaluation of individual tumors in their native microenvironment to ultimately develop more effective therapies. This study will have transformative clinical impact discerning novel metrics for the inclusion of precision medicine for advanced PCa. Citation Format: Ayesha A. Shafi, Matthew J. Schiewer, Renée de Leeuw, Emanuela Dylgjeri, Peter A. McCue, Neelima Shah, Leonard Gomella, Costas Lallas, Edouard Trabulsi, Margaret Centerera, Theresa Hickey, Lisa Butler, Ganesh Raj, Wayne Tilley, Edna Cukierman, Karen E. Knudsen. Patient derived models reveal impact of the tumor microenvironment on therapeutic response [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 112.
THE ASSOCIATION'S AID TO LIBRARIES.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE FATE OF PATHOGENIC BACTERIA IN BURIED CADAVERS.
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Corrigendum to ‘Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)’
Authors: M. Kundranda, A.C. Gracian, S.F. Zafar, E. Meiri, J. Bendell, H. Algül, F. Rivera, E.R. Ahn, D. Watkins, U. Pelzer, V. Charu, A. Zalutskaya, G. Kuesters, J.M. Pipas, S. Santillana, V. Askoxylakis, A.H. Ko
Journal: Annals of Oncology (2020)
NCIC CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer.
Authors: T. J. Whelan, I. Olivotto, I. Ackerman, J. W. Chapman, B. Chua, A. Nabid, K. A. Vallis, J. R. White, P. Rousseau, A. Fortin, L. J. Pierce, L. Manchul, P. Craighead, M. C. Nolan, J. Bowen, D. R. McCready, K. I. Pritchard, M. N. Levine, W. Parulekar
Journal: Journal of Clinical Oncology (2011)

LBA1003 The full, final text of this abstract will be available in Part II of the 2011 Annual Meeting Proceedings, distributed onsite at the Meeting on June 4, 2011, and as a supplement to the June 20, 2011, issue of Journal of Clinical Oncology.
Text-book of Training Schools for Nurses; Including Physiology and Hygiene and the Principles and Practice of Nursing.
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical Impact Of Small TP53 Mutated Subclones In Chronic Lymphocytic Leukemia
Authors: Davide Rossi, Hossein Khiabanian, Carmela Ciardullo, Valeria Spina, Alessio Bruscaggin, Rosella Famà, Sara Monti, Silvia Rasi, Jiguang Wang, Valter Gattei, Anna Guarini, Robin FoÃ, Raul Rabadan, Gianluca Gaidano
Journal: Blood (2013)
Erratum
Journal: BMJ (1898)

M. B. asks for references to literature on the pathology of antenatal ascites.RUSTICUS asks for advice as to treatment of a case of chronic gonorrhbea in a male, contracted August, I897.Thete is a slight morning dis- charge.The ordinary remedies do not seem to improve the con- dition.J. S. S. would be pleased to hear of a home or hospital in or near London where a female patient, sufferiDg from an eruption of the face and general cedema of the body (due, it Is believed, to the absorption of arsenic), could be received and treated.The patient is able to pay a small fee.M. B. asks to be recoiiimended a book to read in mental psychology for
Manuscripts Approved for JNCI, January–February 1975
Journal: JNCI Journal of the National Cancer Institute (1975)

Manuscripts Approved for JNCI, January–February 1975 Get access JNCI: Journal of the National Cancer Institute, Volume 54, Issue 3, March 1975, Page 808, https://doi.org/10.1093/jnci/54.3.808-a Published: 01 March 1975
Ophthalmology
Authors: Leonard A. Levin
Journal: JAMA (1995)

For patients, loss of vision is one of the most feared consequences of ophthalmic or systemic disease. For many, it is second only to death. Basic science and clinical research by visual scientists and ophthalmologists is steadily yielding the means to better prevent, diagnose, and treat diseases that cause blindness and erode our patients' quality of life. Age-related macular degeneration is the leading cause of irreversible blindness in those older than 65 years in the United States, and treatment options are limited in the majority of cases. The pathophysiology involves degenerative changes in the macula or central retina. Recent interest has focused on the role of light-mediated free radical production and subsequent lipid peroxidation mediating damage in this area and, conversely, the role of food and dietary supplements that may block macular degeneration by scavenging free radicals and inhibiting these oxidative processes. The Eye Disease Case-Control Study Group analyzed 356
Overview on AMA activities
Authors: E. B. Howard
Journal: JAMA (1972)

In November 1968, the House noted that the EVP, as the "chief executive officer," had "a unique opportunity to assess the affairs of medicine both internally and in the context of their public impact." It therefore directed the EVP to prepare an annual written report to the House. In 1969,1970, and 1971, my reports dealt exclusively with staff affairs. In this 1972 report I have expanded my review to present a more comprehensive picture of AMA activities. This report did not appear in the House of Delegates<i>Handbook</i>because I wanted it to be up to the minute. It was completed on Friday, June 16. <h3>Ongoing Services</h3> The AMA is a large and complex organization whose wide-ranging, diversified activities are probably unmatched by any voluntary agency in the world. Here is a kaleidoscope of the AMA: 1. In one day at the AMA there are 700 long distance telephone calls
HYPERTENSION AND URIC ACID
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BOOK REVIEW
Authors: S. E. BENNER
Journal: JNCI Journal of the National Cancer Institute (1995)

Journal Article BOOK REVIEW Get access Epidemiology of Lung Cancer Jonathan M. Samet , ed. New York : Marcel Dekker, Inc. , 1994 . 544 pp., illus. $175. ISBN 0-8247-8853-2 STEVEN E. BENNER, M.D., M.H.S. STEVEN E. BENNER, M.D., M.H.S. University of North Carolina at Chapel HillCB #73053009, Old Clinic Building, Chapel Hill, NC 27599 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 87, Issue 9, 3 May 1995, Page 685, https://doi.org/10.1093/jnci/87.9.685 Published: 03 May 1995
Creating a basis for good outcomes
Authors: R. Voelker
Journal: JAMA (1995)

FROM OUTWARD appearances, it might seem that the outcomes research revolution is well under way. Study results are published regularly in the medical literature and clinical outcomes data have helped produce dozens of practice guidelines. But when outcomes research is scrutinized more closely, it appears that the revolution is still very much an evolution. "Is this just another passing fad or is it providing something that's not available through standard clinical trials or certain kinds of process measures?" asked Sheldon Greenfield, MD, director of the Primary Care Outcomes Research Institute at the New England Medical Center in Boston, Mass. Greenfield discussed varying aspects of outcomes research during Prevention 95, the annual meeting sponsored by the American College of Preventive Medicine and the Association of Teachers of Preventive Medicine. Outcomes research has become a critical topic for specialists in preventive medicine. Their emphasis on bringing clinical preventive services to the masses
Literature on the Dual Brain.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Queries and Minor Notes
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
"Munchausen" Cases
Authors: FRANK LIZZI
Journal: Annals of Internal Medicine (1973)

Comments and Corrections1 August 1973"Munchausen" CasesFRANK LIZZI, M.D., ROBERT WHITE, M.D.FRANK LIZZI, M.D.Search for more papers by this author, ROBERT WHITE, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-79-2-290_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: On 14 May 1973 a 29-year-old man of Italian descent was admitted to the Albany Medical Center Hospital with complaints of chest pain and a swollen tender area on his lower leg. He stated that he had discontinued taking sodium warfarin (Coumadin®) 2 weeks previously. He gave a history of inferior vena cava umbrella and ligation, recurrent pulmonary emboli, positive tests for cryoglobulins, and a positive supraclavicular node biopsy for lymphoma.Except for the addition of the lymphoma problem, this case fits precisely that of the man seen in Philadelphia in May 1972 (Ann Intern Med77:477,... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Hematology Division and Department of Medicine Albany Medical Center Hospital Albany, New York PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byMore on "Munchausen Syndrome"RICHARD B. DEVEREUX, M.D., THOMAS R. MILLER, M.D. 1 August 1973Volume 79, Issue 2Page: 290-290KeywordsBiopsyInferior vena cavaIschemiaLigation assayLymphomaSodium Issue Published: 1 August 1973 PDF downloadLoading ...
An ethics consultation service in a teaching hospital. Utilization and evaluation
Authors: J. La Puma
Journal: JAMA (1988)

A newly established formal ethics consultation service in a university teaching hospital was prospectively evaluated. A physician-ethicist interviewed and examined patients, interviewed family and others as needed, and entered a formal consultation note in the medical record. The requesting physician and the consultant independently completed structured questionnaires. Fifty-one consultation requests were received from 45 physicians from seven departments between July 1,1986, and June 30,1987. Seventeen (33%) of 51 patients were in the intensive care unit, and 19 patients (37%) were fully oriented at the time of consultation. Overall, 61% of the patients survived to leave the hospital. The requesting physician sought assistance with withholding or withdrawing lifesustaining treatment in 49% of cases, with resuscitation issues in 37%, and with legal issues in 31% Assistance with more than one issue was sought in 39 cases (76%). In 36 cases (71%), the requesting physician stated that the consultation was "very important" in patient management, in clarifying ethical issues, or in learning about medical ethics. We conclude that ethics consultation performed by physician-ethicists provides useful, clinically acceptable assistance in a teaching hospital. (<i>JAMA</i>1988;260:808-811)
Targeting Glioblastoma with CAR T Cells
Journal: Cancer Discovery (2017)

CAR T cells targeting IL13Rα2 proved effective against recurrent multifocal leptomeningeal glioblastoma, according to a case report. Direct delivery of the therapy into the cerebrospinal fluid was well tolerated, completely eliminating the patient's brain and spinal tumors for 7.5 months, during which the patient resumed his normal activities.